NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

NeoGenomics, Inc.NASDAQ: NEO

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $8.22M fell 32.7% year over year, behind the -29.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 14.7% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Stock-based compensation amounted to 5.7% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -32.7% toward the trailing-twelve-month pace of -29.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.22M-14.7% QoQ
Last fiscal yearDec 2025
$41.32M+23.7% YoY
LTMJun 2026
$28.16M-29.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.7%——
1 year+23.7%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
41.32M USD
Year-over-year change
+23.7%
4-year CAGR
+16.5%

Stock-Based Compensation vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 stock-based compensation of $28.16M is the 6th largest of the 10 companies compared; the peer median is $32.2M.
  • Its year-over-year change of -29.2% is the 8th highest of 10, against a peer median of -4.5%.
  • Stock-based compensation amounts to 3.7% of revenue for NEO, versus a peer median of 7.9%.
NEO Competitors Peer median
Stock-Based Compensation for NEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$210.96M +32.4%+20.6%16.5%
VCYTVeracyte, Inc.LTM Jun 2026$48.51M +20.3%+17.7%8.6%
CSTLCastle Biosciences, Inc.LTM Mar 2026$44.49M -8.9%+8.1%13.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$35.7M +95.3%-8.5%7.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
GRALGRAIL, Inc.LTM Jun 2026$5.97M -90.3%-8.4%3.6%
BDSXBiodesix, Inc.LTM Mar 2026$4.28M -13.8%-11.4%4.5%
XGNExagen Inc.LTM Mar 2026$2.4M +47.3%-22.9%3.5%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding NEO) $32.2M-4.5%-8.4%7.9%

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
Deferred Income Tax0(16.1M)000
Stock-Based Compensation22.46M24.67M24.63M33.41M41.32M
Change in Working Capital(4.6M)(31.7M)(25.49M)(32.63M)(32.1M)
Accounts Receivables(4.69M)(7.58M)(11.52M)(19.31M)(6.18M)
Inventory1.63M(1.1M)(454K)(2.7M)(1.54M)
Accounts Payables19.33M2.8M(4.55M)(4M)(4.69M)
Other Working Capital(20.87M)(25.82M)(8.98M)(6.62M)(19.68M)
Other Non-Cash Items(89.59M)31.95M14.29M12.42M36.21M
Operating Cash Flow(26.72M)(65.99M)(1.95M)7.02M5.23M
Capital Expenditures(64.14M)(30.89M)(28.75M)(41.06M)(27.01M)
Acquisitions (Net)(419.4M)000(6.45M)
Purchases of Investments(196.79M)(97.61M)(6.76M)0(500K)
Sales of Investments62.97M116.92M112.22M53.92M20.06M
Other Investing Activities(15M)12.1M001.57M
Investing Cash Flow(632.37M)517K76.71M12.86M(12.34M)
Debt Repayment334.41M(758K)(70K)0(201.25M)
Common Stock Issued423.21M12.59M4.62M4.65M962K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(32.34M)0000
Financing Cash Flow725.29M11.83M4.55M4.65M(200.29M)
Effect of Forex Changes00000
Net Change in Cash66.2M(53.65M)79.31M24.52M(207.39M)
Free Cash Flow(90.87M)(96.88M)(30.71M)(34.04M)(21.78M)

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.